Dynamics of Chemokine, Cytokine, and Growth Factor Serum Levels in BRAF-Mutant Melanoma Patients during BRAF Inhibitor Treatment-Reference-Cited by-同舟云学术

Dynamics of Chemokine, Cytokine, and Growth Factor Serum Levels in BRAF-Mutant Melanoma Patients during BRAF Inhibitor Treatment

Published:2014-01-31 Issue:5 Volume:192 Page:2505-2513
ISSN:0022-1767
Container-title:The Journal of Immunology
language:en
Short-container-title:J.I.

Author:

Wilmott James S.,Haydu Lauren E.,Menzies Alexander M.,Lum Trina,Hyman Jessica,Thompson John F.,Hersey Peter,Kefford Richard F.,Scolyer Richard A.,Long Georgina V.

Publisher

The American Association of Immunologists

Subject

Immunology,Immunology and Allergy

Reference55 articles.

1. Mutations of the BRAF gene in human cancer

2. Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma

3. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

4. Differential sensitivity of melanoma cell lines with BRAF V600E mutation to the specific Raf inhibitor PLX4032

5. The BRAF–MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Single-cell RNA sequencing reveals melanoma cell state-dependent heterogeneity of response to MAPK inhibitors;eBioMedicine;2024-09

2. Circulating interleukin-8 and osteopontin are promising biomarkers of clinical outcomes in advanced melanoma patients treated with targeted therapy;Journal of Experimental & Clinical Cancer Research;2024-08-15

3. Hemophagocytic lymphohistiocytosis induced by dabrafenib-trametinib in a patient with metastatic melanoma: a case report and pharmacovigilance analysis;Melanoma Research;2024-07-22

4. The role of CCL2/CCR2 axis in cancer and inflammation: The next frontier in nanomedicine;Advanced Drug Delivery Reviews;2024-06

5. The more the merrier? Evidence and efficacy of immune checkpoint- and tyrosine kinase inhibitor combinations in advanced solid cancers;Cancer Treatment Reviews;2024-04